NEW YORK (GenomeWeb News) — Celera said today it has licensed its estrogen/progesterone receptor patents to LabCorp, which will use the IP to commercialize two cancer tests.
 
The reference lab giant will use one test to predict risk of metastasis in early-stage breast cancer, while the other will assess hormone-receptor status to help plan endocrine therapy.
 
Under the agreement, LabCorp will pay Celera an up-front license fee and royalties on net sales of lab services and tests that use the IP.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.